OLC

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

Retrieved on: 
Mercoledì, Maggio 15, 2024
PBS, Patient, PD, Kidney disease, LOS, Dialysis, FDA, National Kidney Foundation, Therapy, Snack, Chronic kidney disease, MD, CKD, Incidence, Șaeș, Poster, Tablet, TID, Hyperphosphatemia, NKF, OLC, BL, Aes, Meal, Quality of life, PB, Pharmaceutical industry

LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), were presented at the National Kidney Foundation (NKF) Spring Clinical Meeting. OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).

Key Points: 
  • LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), were presented at the National Kidney Foundation (NKF) Spring Clinical Meeting.
  • OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
  • “The NKF Spring Clinical Meeting was an important meeting for Unicycive as we were able to present data from the OLC bioequivalence study and our second poster was featured as a top-rated submission,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • Our data confirms that OLC is bioequivalent to lanthanum carbonate (LC) by showing similar outcomes in both groups with respect to mean change in urinary phosphate excretion.

Palliser Capital Proposes Advisory Resolution to Give Shareholders a Voice at Keisei’s Forthcoming AGM

Retrieved on: 
Mercoledì, Aprile 24, 2024
Finance, Rail, Professional Services, Transport, Asset Management, Sale, Capital, Policy, Tokyo Stock Exchange, Exercise, OLC, Multimedia, Government, Letter, Growth, AGM, Security (finance)

Palliser Capital (“Palliser”), the eighth largest shareholder of Keisei Electric Railway Co., Ltd. (9009 JT) (“Keisei” or the “Company”) with a stake of 1.6%, has today submitted a formal proposal to table an advisory resolution focused on capital allocation at Keisei’s forthcoming AGM.

Key Points: 
  • Palliser Capital (“Palliser”), the eighth largest shareholder of Keisei Electric Railway Co., Ltd. (9009 JT) (“Keisei” or the “Company”) with a stake of 1.6%, has today submitted a formal proposal to table an advisory resolution focused on capital allocation at Keisei’s forthcoming AGM.
  • Full details of Palliser's presentation on unlocking and catalyzing growth at Keisei for the benefit of all stakeholders are available at link .
  • The proposed resolution is formulated to be long-term in outlook, non-prescriptive and non-disruptive of other important company business.
  • Palliser has requested confirmation from the Board by 6pm JST on 26 April 2024 that the proposed advisory resolution will be tabled at the AGM.

University of Phoenix Office of Educational Equity Leadership Presents at 2024 OLC Innovate Conference

Retrieved on: 
Venerdì, Aprile 12, 2024
Professional Services, Continuing, University, DEI (Diversity, Equity and Inclusion), Education, Online, Family, CO, American Council, DEIB, University of Phoenix, Trauma, Office, Workplace, Trumbull County, Ohio, Conference, Student, Business, Learning, Risk management, Educational equity, Child, OLC, SOS, Terrain, Growth, Tutoring

University of Phoenix is pleased to share that Office of Educational Equity Program Manager Jelisa Dallas, M.S.

Key Points: 
  • University of Phoenix is pleased to share that Office of Educational Equity Program Manager Jelisa Dallas, M.S.
  • Dallas currently sits on of the board of the University of Phoenix employee resource group, African American Council for Excellence.
  • The Office of Educational Equity leads internal and external initiatives promoting understanding and inclusive practices throughout the University, aligning with the University of Phoenix President’s Advisory Council on Diversity, Equity, Inclusion and Belonging (DEIB).
  • The next Summit, free to the public and themed “Transparency as the catalyst for belonging,” is planned for June 11-13, 2024.

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Marzo 28, 2024
ODD, Research, Hyperphosphatemia, DGF, CRRT, ERA, Administration, Congress, Conference, OLC, CKD, Patient, AKI, National Kidney Foundation, Mitochondrion, NDA, Kidney transplantation, Insurance, Kidney disease, Critical care, Acute kidney injury, Clinical trial, Therapy, Drug development, Safety, Chronic kidney disease, Dialysis, LOS, Research and development, SAD, FDA, KATP, Food, Pharmaceutical industry

LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update.
  • Completed a private placement with new and existing healthcare institutional investors that generated $50 million in gross proceeds to Unicycive.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled $9.7 million.
  • Subsequent to year end, in March 2024, Unicycive completed a private placement of preferred stock which generated $50 million in gross proceeds.

Palliser Capital Commends the Initial Reduction in Keisei’s OLC Stake; Looks Forward to Working with Keisei Management on Further Steps to Unlock Value

Retrieved on: 
Giovedì, Marzo 7, 2024
Professional Services, Rail, Transport, Vacation, Finance, Travel, The Oriental Land Company, Capital, OLC

Palliser Capital (“Palliser”), the eighth largest shareholder of Keisei Electric Railway Co., Ltd. (9009 JT) (“Keisei” or the “Company”) with a stake of 1.6% commends Keisei’s decision to reduce the size of its stake in the Oriental Land Company (“OLC”) and is encouraged that the capital released will be used to bolster shareholder returns and fund strategic and growth initiatives.

Key Points: 
  • Palliser Capital (“Palliser”), the eighth largest shareholder of Keisei Electric Railway Co., Ltd. (9009 JT) (“Keisei” or the “Company”) with a stake of 1.6% commends Keisei’s decision to reduce the size of its stake in the Oriental Land Company (“OLC”) and is encouraged that the capital released will be used to bolster shareholder returns and fund strategic and growth initiatives.
  • Palliser believes this marks a pivotal change in the strategic direction of the Company, but that further action is needed to resolve the accounting distortion that arises from maintaining an outsized stake in OLC, which masks Keisei’s true price-to-book ratio that remains materially below 1.0x.
  • Palliser looks forward to continuing its ongoing constructive engagement with Keisei’s management team to implement additional near-term measures to unlock the Company’s intrinsic value for all its stakeholders, including further OLC disposals, enhanced capital allocation, and improved corporate governance and investor communication.

University of Phoenix Leadership to Present at Greater Phoenix Chamber Event

Retrieved on: 
Venerdì, Febbraio 23, 2024
Professional Services, Education, DEI (Diversity, Equity and Inclusion), Business, Human Resources, Continuing, University, Online, Social capital, Culture, Growth, Commerce, Society, MST, UPCEA, Organization, Higher education, Workforce, Woman, Student, CHEA, Phoenix metropolitan area, Grinnell College, Assessment, SCCE, Faculty, Higher Learning Commission, Curriculum, Chamber, Conference, University of Phoenix, Equity, Accreditation, Research, DEI, Online and offline, Q&A, OLC, Nursing

University of Phoenix proudly presents its distinguished leaders as featured speakers at the Greater Phoenix Chamber's quarterly Diversity, Equity & Inclusion (DEI) Forum.

Key Points: 
  • University of Phoenix proudly presents its distinguished leaders as featured speakers at the Greater Phoenix Chamber's quarterly Diversity, Equity & Inclusion (DEI) Forum.
  • "We are thrilled to have Doris Savron and McCeil Johnson from the University of Phoenix as our speakers for this significant DEI Forum," said Todd Sanders, President and CEO of the Greater Phoenix Chamber.
  • “As we engage in this collaborative event with the Greater Phoenix Chamber, we appreciate the pivotal role they play in shaping a diverse and inclusive professional landscape,” she shares.
  • She recently completed a six-year term at the Greater Phoenix Chamber of Commerce and serves on committees like the DEI professionals committee for the Chamber.

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

Retrieved on: 
Mercoledì, Febbraio 14, 2024
National Kidney Foundation, Kidney disease, Patient, Therapy, OLC, LOS, MD

LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.

Key Points: 
  • LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.
  • “We are proud to present two posters related to OLC at the National Kidney Foundation Spring Clinical Meeting, one of the premier medical conferences for the healthcare community focused on kidney disease,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • “Importantly, we will present new data from the bioequivalence study for OLC.
  • We will also present results of a survey conducted to understand why patients may be non-compliant in taking the currently prescribed phosphate binders.

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

Retrieved on: 
Lunedì, Gennaio 29, 2024
LOS, Patient, Therapy, MD, AKI, Kidney disease, Critical care, Conference, CRRT, Acute kidney injury, OLC, Kidney transplantation, Pharmaceutical industry

Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “We are looking forward to presenting data on the efficacy of our second clinical stage program UNI-494 in animal models of delayed graft function, a manifestation of acute kidney injury (AKI) that occurs during kidney transplantation resulting in loss of kidney function.

Key Points: 
  • Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “We are looking forward to presenting data on the efficacy of our second clinical stage program UNI-494 in animal models of delayed graft function, a manifestation of acute kidney injury (AKI) that occurs during kidney transplantation resulting in loss of kidney function.
  • We are also presenting a poster describing our ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers.
  • Based on the results from this trial, we will determine the best path forward for the program.
  • While our primary focus is on advancing our lead drug, OLC (Oxylanthanum Carbonate) towards a New Drug Application submission, we continue to build a body of data on UNI-494 as it progresses through its first clinical trial.”

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

Retrieved on: 
Lunedì, Dicembre 18, 2023
Hyperphosphatemia, Quality of life, Physician, OLC, TID, Kidney disease, Trial of the century, NDA, MD, Therapy, Pharmacokinetics, Chronic kidney disease, LOS, Patient, Safety, Dialysis, CKD, Pharmaceutical industry

LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC).

Key Points: 
  • LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC).
  • OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
  • “The initiation of patient enrollment in our OLC pivotal clinical trial is a critical milestone as we strive to reduce the pill burden and improve quality of life for individuals with chronic kidney disease on dialysis,” said, Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • Once titrated to a clinically effective dose, participants will then be treated for four weeks to evaluate serum phosphate levels.

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Novembre 14, 2023
NDA, Chronic kidney disease, Hyperphosphatemia, Chemistry, Food, Therapy, Type, IND, Kidney disease, Clinical trial, Administration, Insurance, Patient, LOS, Agency, Research, Dialysis, FDA, Pharmacokinetics, Nephrology, Trial of the century, R, CMC, Research and development, Doctor of Philosophy, American Journal, Society, Travel, Drug development, Pharmaceutical industry, Management, OLC

LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • We also remain very active within the the medical community with a booth at Kidney Week and positive results published on the phosphate binding capacity for OLC,” concluded Dr. Gupta.
  • Unicycive believes that results from this pivotal trial will enhance the OLC data package from preclinical studies and our previously disclosed bioequivalence study.
  • Dr. Kenkare-Mitra brings Unicycive expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory.